Peter you did an incredible job highlighting what fuels us. We never accept less than curing every single patient that walks through our doors. You embody this and your patient’s words were so touching. A big thanks to the Schultz family in empowering us to touch many more lives
🚨New episode of #TheImmunoVerse out today!
What happens when a study fails? And what happens when the results surprise you?
Dr. Ben Creelan (@BenCreelan) and I talk about both, from taking risks as a young scientist to seeing some lung tumors shrink in an early cell therapy trial. @MoffittNews
🎧 Listen now at https://t.co/1kauiQwmpj or on any major podcast platform.
The House has included $10 million for an Endometrial Cancer Research Program in FY2027 Defense appropriations bill.
Download SGO's Advocacy Social Media Toolkit: personalize posts, tag your representatives, spread the word.
https://t.co/bHIKkQnfdN
Join us in congratulating Moffitt President and CEO Patrick Hwu, MD (@patrickhwumd), on his induction into the Florida Inventors Hall of Fame!
His pioneering research helped lay the groundwork for CAR T-cell therapy, which reprograms a patient’s immune cells to recognize and attack cancer. Today, he continues to advance discoveries that could bring new treatment options to more patients.
We’re proud to celebrate his decades of innovation and dedication to changing the future of cancer care!
🔷 Toward prolonged disease control: dMMR endometrial cancer in the immunotherapy era
For years, carboplatin + paclitaxel was the standard first-line backbone for primary advanced or recurrent endometrial cancer, before molecular classification began to reshape treatment selection. Following ESMO 2026, the label-based evidence showing how immunotherapy has reshaped the PFS benchmark in dMMR disease, through the regimens studied in RUBY, KEYNOTE-868/NRG-GY018 and DUO-E. These separate trials illustrate the shift but do not establish comparative efficacy between regimens.
🔷 KEYNOTE-C93: a potential chemotherapy-free first-line approach?
At @myESMO 2026 (LBA12), phase 3 KEYNOTE-C93 showed improved PFS with pembrolizumab alone versus carboplatin + paclitaxel in dMMR advanced or recurrent endometrial cancer (median 38.2 vs 8.4 months; HR 0.57). OS numerically favored pembrolizumab (HR 0.77), without statistical significance; 85% of chemo-arm progressors later received IO.
With checkpoint inhibitors now established in first-line dMMR disease and a chemotherapy-free option emerging, where does the next step change come from? Smarter IO combinations, earlier use in the curative setting, or something else?
Explore #ESMO26 insights here: https://t.co/JBaV2QEuxu
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #EndometrialCancer #GynecologicOncology #GYNSM #Immunotherapy #CompetitiveIntelligence | @ErikaHamilton9 | @ShannonWestin | @Sushilberiwal | @DrBarbiOnc | @drteplinsky | @MAvilaMD
I thought #ESMO26 was the year of IO and this CART just came out of nowhere to smash expectations
🤯 Is this real?
SL-28 (1002O): off-the-shelf allogeneic leukocytes from healthy donors. No genetic modification, no HLA matching, no conditioning. 12 heavily pretreated patients.
• ORR 66.7% (4 CR, 4 PR) • 4 SD, 0 PD • mDoR not reached in responders • mPFS 24.7 mo
• 4 of 12 patients died, all labeled non-cancer related. In a cell therapy dataset I need to know what killed them.
• The 12 mix a Phase 1/2 that started in 2026 with expanded-access patients. A 24.7 mo median PFS likely utilizes the compassionate-use cases.
• SL-28 runs on "TezR" receptors, a system first described by the company's founders (one of whom presented today). I'd love to see someone else replicate it.
Have we finally entered the era of solid tumor CAR-Ts?
@OncoAlert@TheGutOncLab@Onco_Nexus
Loved hearing @ErinGeorgeMD's perspective at #BMES2026. We talked about her work building ovarian cancer models from patient samples to better understand how each tumor responds to treatment. Excited to see where this work goes! @MoffittNews#MoffittBMES26
We're ushering in a new era of care🌅!Announcing🚨 at #IPVS2026 the opening of a multidisciplinary clinic 🤝@MoffittNews around #HPV dx and rather than organ sites: a venture bw @MoffittGYNONC & #Colorectal surgery for care optimization & best practices for screening, tx and surveillance of pan anogenital dx 📋Grateful Julian Sanchez for our partnership and @AnnaGiuliano19 for your mentorship & support!
@RMWenham@biancatng1
CAR-T without manufacturing the CAR-T?
Legend Biotech has received FDA IND clearance for LB2501, an investigational in vivo CAR-T therapy designed to generate CD19/CD20 dual-targeting CAR-T cells directly inside the patient after a single infusion.
Unlike conventional autologous CAR-T, LB2501 is designed to be off-the-shelf, potentially eliminating several steps of individualized cell collection and manufacturing. Notably, the planned U.S. Phase 1/2 study will evaluate the therapy without lymphodepleting chemotherapy.
LB2501 uses Legend’s TaVec™ platform, an engineered, replication-incompetent lentiviral vector designed to selectively transduce T cells in vivo. The resulting CAR-T cells target both CD19 and CD20—a strategy intended to reduce the risk of antigen escape in B-cell malignancies.
If successful, this could address some of the biggest barriers to conventional CAR-T: manufacturing time, complexity, scalability, and access.
But the critical questions now move from engineering to the clinic:
Can we reliably generate enough functional CAR-T cells in vivo?
Will the cells expand and persist appropriately?
What will the safety profile look like without traditional lymphodepletion?
And can dual targeting translate into deeper and more durable responses?
LB2501 is now moving toward U.S. clinical evaluation, adding another important step in the rapidly developing field of in vivo cell engineering.
The next generation of CAR-T may not be manufactured for the patient—it may be manufactured inside the patient.
https://t.co/yf1RWwfVYT
#CART #InVivoCART #CellTherapy #Immunotherapy #Lymphoma #Hematology #BCellLymphoma #CancerResearch
At #IPVS2026, presenting our review of GYN/GI OR 🏥 cases for anogenital HPV dx @MoffittNews: highlighting a MUCH higher ⬆️ than historically described (20%) concomitant risk of anogenital dysplasia or cancer when screened simultaneously!! 82% in our more immunosuppressed pop. More consistent with now updated #IANS guide to screen 📺 all with at least prior hx #GYN cancer (but also perhaps dysplasia?)
Julian Sanchez @AnnaGiuliano19@RMWenham@biancatng1@MoffittNews@MoffittGYNONC
🏆 #FollowFriday Meet Monica Avila, MD (@MAvilaMD), winner of our Conference MVP Award! She leads by example, sharing research, celebrating colleagues and engaging with the scientific community at conferences. Congratulations, Dr. Avila! 👏 #MoffittAmbassadors